{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:34:35Z","timestamp":1771054475599,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd000458.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000}}],"reference-count":144,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000458.pub3","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T23:11:49Z","timestamp":1516230709000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Hany G","family":"El-Sayeh","sequence":"first","affiliation":[{"name":"Tees, Esk & Wear Valleys NHS Foundation Trust; Harrogate District Hospital; Briary Wing Lancaster Park Road Harrogate North Yorkshire UK HG2 7SX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rathbone","sequence":"additional","affiliation":[{"name":"Bond University; Faculty of Health Sciences and Medicine; Robina Gold Coast Queensland Australia 4229"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Soares-Weiser","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Editorial Unit; St Albans House, 57 - 59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0404.1982.tb03059.x","article-title":"Tiapride in the treatment of tardive dyskinesia","volume":"65","author":"Buruma","year":"1982","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0002|cit2","first-page":"1234","article-title":"Tiapride in Huntington's chorea and tardive dyskinesia. A double-blind, placebo controlled crossover clinical trial","volume":"7","author":"Roos","year":"1982","journal-title":"Tijdschrift voor Geneesmiddelenonderzoek"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0003|cit3","first-page":"203","article-title":"A double-blind auto-control study on the effect of bromocriptine on tardive dyskinesia","volume":"4","author":"Chen","year":"1995","journal-title":"Chinese Journal of Pharmaco Epiolemiology"},{"issue":"12","key":"10.1002\/14651858.CD000458.pub3-BIB0004|cit4","first-page":"388","article-title":"Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics","volume":"98","author":"Hebenstreit","year":"1986","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0005|cit5","first-page":"41","article-title":"Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia","volume":"16","author":"Huang","year":"1980","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00426466","article-title":"Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia","volume":"73","author":"Huang","year":"1981","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0007|cit7","first-page":"261","article-title":"A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia","volume":"29","author":"Karniol","year":"1983","journal-title":"Acta Psiquiatrica y Psicologica de America Latina"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000458.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0010|cit10","unstructured":"Pappa S Tsouli S Apostolou G Mavreas V Konitsiotis S Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study 9th World Congress of Biological Psychiatry; 28 June-2 July 2009; Paris, France 2009 171"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/S0920-9964(12)71045-9","article-title":"Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study","volume":"136","author":"Pappa","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"30","key":"10.1002\/14651858.CD000458.pub3-BIB0012|cit12","first-page":"2195","article-title":"Tiapride treatment of tardive dyskinesia due to long-term neuroleptic treatment","volume":"60","author":"Rust","year":"1984","journal-title":"Semaine des Hopitaux"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000458.pub3-BIB0013|cit13","first-page":"S49","article-title":"Double-blind carbidopa-levodopa and placebo study in tardive dyskinesia","volume":"8","author":"Simpson","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD000458.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1600-0447.1986.tb06267.x","article-title":"Oxypertine in tardive dyskinesia: a long-term controlled study","volume":"74","author":"Soni","year":"1986","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD000458.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0006-3223(90)90540-I","article-title":"Metoprolol versus propranolol","volume":"27","author":"Adler","year":"1990","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0016|cit16","first-page":"253","article-title":"Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia","volume":"37","author":"Alpert","year":"1983","journal-title":"Advances in Neurology"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","article-title":"A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia","volume":"17","author":"Angus","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD000458.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","article-title":"Tetrabenazine and movement disorders","volume":"31","author":"Asher","year":"1981","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-1017312","article-title":"Tiapride in the treatment of tardive dyskinesia. A double-blind study","volume":"18","author":"Auberger","year":"1985","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000118195","article-title":"Tiapride: effects on tardive dyskinesia and on prolactin plasma concentrations","volume":"14","author":"Greil","year":"1985","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1192\/bjp.135.6.505","article-title":"Metoclopramide and haloperidol in tardive dyskinesia","volume":"135","author":"Bateman","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0022|cit22","first-page":"475","article-title":"The effect of metoclopramide and haloperidol on tardive dyskinesia","volume":"66","author":"Bateman","year":"1979","journal-title":"British Journal of Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD000458.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jnnp.52.5.631","article-title":"Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders","volume":"52","author":"Braun","year":"1989","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-198604000-00005","article-title":"The use of clonidine in the treatment of neuroleptic induced tardive dyskinesia","volume":"6","author":"Browne","year":"1986","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0025|cit25","first-page":"20","article-title":"Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia","volume":"14","author":"Chien","year":"1978","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0026|cit26","first-page":"725","article-title":"Clinical trial of tiapride in patients with dyskinesia","volume":"58","author":"Chouza","year":"1982","journal-title":"Semaine des Hopitaux"},{"issue":"35-6","key":"10.1002\/14651858.CD000458.pub3-BIB0027|cit27","first-page":"1585","article-title":"Controlled therapeutic study of spontaneous bucco-linguo-facial dyskinesias (author's translation)","volume":"55","author":"Delwaide","year":"1979","journal-title":"Semaine des Hopitaux"},{"issue":"7","key":"10.1002\/14651858.CD000458.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archneur.1980.00500560071010","article-title":"Bromocriptine and Buccolinguofacial Dyskinesias in Patients With Senile Dementia","volume":"37","author":"Delwaide","year":"1980","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-2003-42166","article-title":"Tardive dyskinesia: pergolid, a possible therapeutic option","volume":"30","author":"Diehl","year":"2003","journal-title":"Psychiatrische Praxis"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Diehl A Dittmann RW Gattaz W Rubin M Hundemer HP Low dose pergolide in the treatment of tardive dyskinesia (td): a double blind, placebo controlled randomised cross over trial 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 243","DOI":"10.1016\/S0924-977X(99)80549-5"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Diehl A Hundemer HP Rubin M Dittmann RW Gattaz W Low-dose pergolide in the treatment of tardive dyskinesia (TD): a double-blind, placebo-controlled randomized cross-over trial Journal of the European College of Neuropsychopharmacology 1999 S359 21040493","DOI":"10.1016\/S0924-977X(99)80549-5"},{"issue":"5","key":"10.1002\/14651858.CD000458.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/archpsyc.1976.01770050055008","article-title":"A controlled trial of amantadine in drug-induced extrapyramidal disorders","volume":"33","author":"DiMascio","year":"1976","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0033|cit33","first-page":"31","article-title":"A controlled trial of amantadine in drug-induced extrapyramidal disorders","volume":"13","author":"DiMascio","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD000458.pub3-BIB0034|cit34","first-page":"376","article-title":"Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia","volume":"2","author":"Doongaji","year":"1982","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0035|cit35","first-page":"267","article-title":"Long term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents","volume-title":"Advances in Neurology: Experimental Therapeutics of Movement Disorders","author":"Fahn","year":"1983"},{"issue":"8","key":"10.1002\/14651858.CD000458.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1176\/ajp.133.8.940","article-title":"Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism","volume":"133","author":"Fann","year":"1976","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD000458.pub3-BIB0037|cit37","first-page":"610","article-title":"Experimental design of a pilot study on amantadine in the extrapyramidal syndrome induced by neuroleptic drugs","volume":"111","author":"Ferrari","year":"1972","journal-title":"Bollettino Chimico Farmaceutico"},{"issue":"5","key":"10.1002\/14651858.CD000458.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000468451","article-title":"A controlled trial of oxypertine in tardive dyskinesia","volume":"15","author":"Freeman","year":"1980","journal-title":"International Pharmacopsychiatry"},{"issue":"5-6","key":"10.1002\/14651858.CD000458.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0364-7722(79)90008-0","article-title":"The effects of papaverine in tardive dyskinesia","volume":"3","author":"Gardos","year":"1979","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD000458.pub3-BIB0041|cit40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1176\/ajp.134.7.781","article-title":"The relationship betwen parkisonism and tardive dyskinesia","volume":"134","author":"Gerlach","year":"1977","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0040|cit41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000468206","article-title":"The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment","volume":"11","author":"Gerlach","year":"1976","journal-title":"Internal Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0042|cit42","unstructured":"Glover O Alternative treatment modalities for drug induced psychomotor dysfunctions PhD dissertation submitted to the Wright Institute 1980 150"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.4.5778.25","article-title":"Persistant phenothiazine dyskinesia treated with tetrabenazine","volume":"4","author":"Godwin Austen","year":"1971","journal-title":"British Medical Journal"},{"issue":"10","key":"10.1002\/14651858.CD000458.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/0006-3223(93)90119-X","article-title":"A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia","volume":"33","author":"Goff","year":"1993","journal-title":"Biological Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD000458.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1176\/ajp.145.10.1318a","article-title":"Lack of efficacy of pindolol in tardive dyskinesia","volume":"145","author":"Greendyke","year":"1988","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0046|cit46","first-page":"181","article-title":"Controlled study on the possibilities of L-dopa in the residual extrapyramidal syndrome caused by neuroleptics","volume":"7","author":"Gutierrez","year":"1979","journal-title":"Actas Luso Espanolas de Neurologia Psiquiatria y Ciencias Afines"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0048|cit47","first-page":"309","article-title":"Metoclopramide in tardive dyskinesia","volume":"14","author":"Hemnani","year":"1982","journal-title":"Indian Journal of Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0047|cit48","first-page":"134","article-title":"Metoclopramide in tardive dyskinesia","volume":"25","author":"Hemnani","year":"1983","journal-title":"Indian Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study","volume":"11","author":"Jankovic","year":"1982","journal-title":"Annals of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD000458.pub3-BIB0050|cit50","first-page":"1085","article-title":"Low-dose apomorphine and bromocriptine in neuroleptic-induced movement disorders","volume":"18","author":"Jeste","year":"1983","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000119254","article-title":"Amantadine versus biperiden - a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders","volume":"33","author":"Konig","year":"1996","journal-title":"Neuropsychobiology"},{"issue":"5","key":"10.1002\/14651858.CD000458.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00002826-198710000-00009","article-title":"Treatment of permanent tardive dyskinesia with tiapride, a selective D2-receptor blocking agent","volume":"10","author":"Leblhuber","year":"1987","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1002\/14651858.CD000458.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archpsyc.1984.01790160106014","article-title":"Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses","volume":"41","author":"Levy","year":"1984","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00004714-198808000-00004","article-title":"Pharmacologic characterization of tardive dyskinesia","volume":"8","author":"Lieberman","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD000458.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1001\/archpsyc.1989.01810100050009","article-title":"Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy","volume":"46","author":"Lieberman","year":"1989","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000458.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004714-198912000-00006","article-title":"The behavioral toxicity of bromocriptine in patients with psychiatric illness","volume":"9","author":"Perovich","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00004714-198902000-00008","article-title":"Stable remission of tardive dyskinesia by L-dopa","volume":"9","author":"Ludatscher","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0059|cit59","first-page":"56","article-title":"Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: Implications for clinical management","volume":"47","author":"Nasrallah","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0060|cit60","unstructured":"NCT00310661 A dual-centre, double-blind, randomized, placebo-controlled, parallel-group study to determine the effects of various adjunctive doses of sarizotan in the treatment of patients with neuroleptic-induced tardive dyskinesia www.ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0061|cit61","unstructured":"NCT00845000 Acute effects of SCH 420814 on dyskinesia and Parkinsonism in levodopa treated patients www.ClinicalTrials.gov"},{"issue":"7","key":"10.1002\/14651858.CD000458.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","article-title":"A randomized trial of amantadine in Huntington disease","volume":"60","author":"O'Suilleabhain","year":"2003","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0165-1781(82)90068-3","article-title":"Naloxone, tardive dyskinesia, and endogenous beta-endorphin","volume":"7","author":"Reker","year":"1982","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0028-1094589","article-title":"Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)","volume":"11","author":"Ringwald","year":"1978","journal-title":"Pharmakopsychiatrie und Neuropsychopharmakologie"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0065|cit65","first-page":"361","article-title":"Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study","volume":"45","author":"Rondot","year":"1987","journal-title":"Advances in Neurology"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0066|cit66","first-page":"167","article-title":"No difference in the effect of biperiden and amantadine on Parkisonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients","volume":"56","author":"Silver","year":"1995","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD000458.pub3-BIB0067|cit67","first-page":"435","article-title":"No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: A double- blind crossover, PLACEBO-controlled study in medicated chronic schizophrenic patients","volume":"56","author":"Silver","year":"1995","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD000458.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1176\/ajp.134.7.763","article-title":"Effects of dopamine agonists in tardive dyskinesia","volume":"134","author":"Smith","year":"1977","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0069|cit69","unstructured":"Stearns AI Sambunaris A Elkashef AM Issa F Egan MF Wyatt RJ Selegiline for negative symptoms and tardive dyskinesia Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, USA American Psychiatric Association 1996"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/archneur.1980.00500530042004","article-title":"Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia","volume":"37","author":"Tamminga","year":"1980","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0071|cit71","first-page":"417","article-title":"Effect of methyldopa on tardive dyskinesia in psychogeriatric patients","volume":"18","author":"Viukari","year":"1975","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub3","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Alabed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD000458.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0074|cit74","unstructured":"Tardive dyskinesia: a task force report of the American Psychiatric Association American Psychiatric Association 1992"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb05604.x","article-title":"Should we cross off the crossover?","volume":"32","author":"Armitage","year":"1991","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD000458.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4088\/JCP.v69n1008","article-title":"Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study","volume":"69","author":"Ascher-Svanum","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-200004000-00011","article-title":"Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies","volume":"20","author":"Ballesteros","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0078|cit78","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects","volume-title":"Antipsychotic drugs and their side-effects","author":"Barnes","year":"1993"},{"issue":"8","key":"10.1002\/14651858.CD000458.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.154.4.523","article-title":"The course of tardive dyskinesia in patients on long-term neuroleptics","volume":"154","author":"Bergen","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"43","key":"10.1002\/14651858.CD000458.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21430","article-title":"Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia","volume":"21","author":"Bergman","year":"2017 Aug","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Bhoopathi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0084|cit84","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-198604000-00005","article-title":"The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia","volume":"6","author":"Browne","year":"1986","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radical in neuroleptic-induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0087|cit87","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Casey","year":"1994"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/npp.1993.26","article-title":"Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and persistence","volume":"8","author":"Cavallaro","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCP.0b013e3181929f94","article-title":"Mortality rates among patients with schizophrenia and tardive dyskinesia","volume":"29","author":"Chong","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychotherapy and Psychosomatics"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0094|cit94","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD000458.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD000458.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD000458.pub3-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub3","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Essali","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up","volume":"56","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0101|cit101","article-title":"The crossover study","volume-title":"The Design and Analysis of Clinical Experiments","author":"Fleiss","year":"1984"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0010-440X(77)90001-3","article-title":"Receptor sensitivity modification (RSM): a new paradigm for the potential treatment of some hormonal and transmitter disturbances","volume":"18","author":"Friedhoff","year":"1977","journal-title":"Comprehensive Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD000458.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1192\/bjp.157.4.585","article-title":"Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication","volume":"157","author":"Glazer","year":"1990","journal-title":"British Journal of Psychiatry"},{"issue":"suppl 4","key":"10.1002\/14651858.CD000458.pub3-BIB0105|cit105","first-page":"15","article-title":"Review of incidence studies of tardive dyskinesia associated with typical antipsychotics","volume":"61","author":"Glazer","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0107|cit107","article-title":"Clinical Global Impressions","volume-title":"Manual for the ECDEU Assessment Battery 2. Rev ed","author":"Guy","year":"1970"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0108|cit108","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Revised Edition","author":"Guy","year":"1976"},{"issue":"7414","key":"10.1002\/14651858.CD000458.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0110|cit110","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org."},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"49S","DOI":"10.1097\/00004714-198808001-00008","article-title":"Pharmacological treatments of tardive dyskinesia in the 1980s","volume":"8","author":"Jeste","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"suppl 4","key":"10.1002\/14651858.CD000458.pub3-BIB0113|cit113","first-page":"27","article-title":"Tardive dyskinesia in older patients","volume":"61","author":"Jeste","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7303","key":"10.1002\/14651858.CD000458.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u0171ni","year":"2001","journal-title":"BMJ (Clinical research ed.)"},{"issue":"4","key":"10.1002\/14651858.CD000458.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0116|cit116","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"11","key":"10.1002\/14651858.CD000458.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000458.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"Supplement 29","key":"10.1002\/14651858.CD000458.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"British Journal of Psychiatry"},{"issue":"5 Suppl B","key":"10.1002\/14651858.CD000458.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0123|cit123","first-page":"44","article-title":"Prevalence of tardive dyskinesia and all-cause mortality amongst patients in a large psychiatirc institute in Rio de Janeiro","volume":"38","author":"Martins","year":"2011","journal-title":"Revista de Psiquiatria Cl\u00ednica"},{"issue":"15","key":"10.1002\/14651858.CD000458.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomised Trials","volume":"285","author":"Moher","year":"2001","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0125|cit125","unstructured":"NICE Psychosis and schizophrenia in adults: treatment and management NICE clinical guideline 178 (guidance.nice.org.uk\/cg178) 2014"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0127|cit127","article-title":"Crossover trials","volume-title":"Clinical trials. A practical approach","author":"Pocock","year":"1983"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/j.1440-1614.2000.00737.x","article-title":"The Current Status of Tardive Dyskinesia","volume":"34","author":"Sachdev","year":"2000","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0129|cit129","first-page":"431","article-title":"Clinical research for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD000458.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0131|cit131","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","article-title":"Changes in prevalence, severity and recovery in tardive dyskinesia with age","volume":"37","author":"Smith","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD000458.pub3-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handbook of Clinical Neurology \/ Edited by P.J. Vinken and G.W. Bruyn"},{"key":"10.1002\/14651858.CD000458.pub3-BIB0139|cit139","doi-asserted-by":"crossref","DOI":"10.3109\/9780203092835","volume-title":"The Maudsley Prescribing Guidelines (10th Edition)","author":"Taylor","year":"2009"},{"issue":"2","key":"10.1002\/14651858.CD000458.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/070674376901400212","article-title":"Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics","volume":"14","author":"Tetreault","year":"1969","journal-title":"Canadian Psychiatric Association Journal"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/apt.11.1.58","article-title":"Psychiatric side-effects of medications: recent developments","volume":"11","author":"Turjanski","year":"2005","journal-title":"Advances in Psychiatric Treatment"},{"issue":"5","key":"10.1002\/14651858.CD000458.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD000458.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD000458.pub3-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000458.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T22:15:44Z","timestamp":1751235344000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000458.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,18]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000458.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,18]]}}}